Excellence In Peripheral Artery Disease Thrombin Receptor Antagonist Intervention In Claudication Evaluation (XLPAD-TRACE Trial)

Trial Profile

Excellence In Peripheral Artery Disease Thrombin Receptor Antagonist Intervention In Claudication Evaluation (XLPAD-TRACE Trial)

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 21 Dec 2016

At a glance

  • Drugs Vorapaxar (Primary) ; Aspirin
  • Indications Thrombosis
  • Focus Therapeutic Use
  • Acronyms XLPAD-TRACE
  • Most Recent Events

    • 27 Jul 2016 Planned primary completion date changed from 1 Jun 2017 to 1 Jul 2017.
    • 27 Jul 2016 Status changed from not yet recruiting to recruiting.
    • 23 Mar 2016 Study design changed from open label to double blind; patients' minimum age changed from 18 years to 40 years, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top